Skip to main content
. 2019 Jan 23;133(13):1495–1506. doi: 10.1182/blood-2018-07-866095

Figure 5.

Figure 5.

Arsenic drives elimination of FLT3ki APLs. (A) ATRA/As-induced differentiation of P/R (top) and P/R-FLT3ki (bottom) bone marrow cells, as assessed by MGG staining (scale bar 10, µm) and FACS analysis after 2, 6, 8, and 12 days of in vivo treatment. GFP-positive leukemic cells (pink) and GFP-negative normal cells (blue) are shown. (B) Percentages of GFP-positive APL cells in bone marrow of untreated (UT) and ATRA/As-treated P/R (red bars) and P/R-FLT3ki (blue bars) mice at 2 to 12 days posttreatment. (C) Proportion of annexin-V (left) and active caspase-3 (right)-positive spleen cells in APL mice treated for 4 days, as indicated. (D) Western blot of PML/RARA (P/R, arrowheaded) and vinculin (Vcl) expression in the bone marrow of P/R-FLT3ki APL UT and ATRA/As-treated mice from 2 to 12 days. (E) PML NB reformation assessed by immunofluorescence analysis of mPML (green) and human PML/RARA (red) with 4′,6-diamidino-2-phenylindole (DAPI) (blue) in bone marrow cells of P/R and P/R-FLT3ki APL mice treated with ATRA/As after 2 days (scale bar, 10 µm).